Continuous Therapy With Certolizumab Pegol Maintains Remission of Patients With Crohn's Disease for up to 18 Months
Section snippets
Study Design
PRECiSE 3 (www.clinicaltrials.gov; NCT00160524) is an ongoing, open-label extension study that included patients who completed 26 weeks of therapy in the PRECiSE 2 trial. The methodology of PRECiSE 2 has been published previously.12, 13 All patients were aged 18 years and older with moderate-to-severe Crohn's disease (defined by a CDAI score between 220 and 450 points) affecting the terminal ileum, colon, or both the ileum and colon for at least 3 months' duration before screening. Diagnoses
Patients and Demographics
In the PRECiSE 2 study, 428 of 668 patients (64.1%) responded to certolizumab pegol induction therapy at week 6 (ie, CDAI decrease of ≥100 points from baseline) and were randomized to receive either certolizumab pegol or placebo maintenance treatment.13 Of the 428 patients, 215 and 210 patients were randomized and received certolizumab pegol or placebo, respectively (3 randomized patients were excluded because of possible unblinding), and 151 patients (69.9%) and 109 patients (51.4%),
Discussion
These results from the PRECiSE 3 trial represent safety and efficacy data from a clinical trial of patients with Crohn's disease receiving either continuous or interrupted anti–TNF-α therapy beyond 12 months without the option to increase the dose. In clinical practice, anti–TNF-α therapy might be stopped temporarily when there is a serious infection such as pneumonia. Therefore, clinical trial data on the potential implications of interrupted therapy provide directly relevant clinical
Acknowledgments
Medical writing assistance was provided by Lisa Thomas, PhD (PAREXEL, West Sussex, UK) and was funded by UCB, Brussels.
A committee of academic investigators and UCB scientists designed the study. The trial was registered with clinicaltrials.gov (NCT00160524). Data were collected by ICON Clinical Research, Hampshire, United Kingdom, and were analyzed by UCB. The academic authors vouch for the veracity and completeness of the data and data analyses.
References (24)
- et al.
Tumour necrosis factor alpha and interleukin 1 beta in relapse of Crohn's disease
Lancet
(1999) - et al.
Tumour necrosis factor alpha in stool as a marker of intestinal inflammation
Lancet
(1992) - et al.
Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial
Gastroenterology
(2006) - et al.
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial
Lancet
(2002) - et al.
Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial
Gastroenterology
(2007) - et al.
Diagnostics of inflammatory bowel disease
Gastroenterology
(2007) - et al.
A simple index of Crohn's-disease activity
Lancet
(1980) - et al.
Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease
Gastroenterology
(2004) - et al.
European evidence based consensus on the diagnosis and management of Crohn's disease: current management
Gut
(2006) - et al.
Tumour necrosis factor-alpha and interferon-gamma production measured at the single cell level in normal and inflamed human intestine
Clin Exp Immunol
(1990)
Serum concentrations of tumour necrosis factor alpha in childhood chronic inflammatory bowel disease
Gut
A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's diseaseCrohn's Disease cA2 Study Group
N Engl J Med
Cited by (0)
Conflicts of interest The authors disclose the following: Gary R. Lichtenstein reports receiving consulting fees from Abbott Laboratories, Centocor, Ferring, Tanabe, Schering-Plough, Elan Pharmaceuticals, Genentech, Given Imaging, Millennium Pharmaceuticals, Proctor and Gamble, Prometheus, Salix, Shire, UCB Pharma, and Wyeth; receiving lecture fees from Abbott Laboratories, Centocor, Proctor and Gamble, Salix, and UCB Pharma; research with Abbott Laboratories, AstraZeneca, Bristol-Meyers Squibb, Proctor and Gamble, Salix, and Shire. Ole Ø. Thomsen reports receiving consulting fees from UCB and Zealand Pharma and receiving lecture fees from AstraZeneca, Dr Falk Pharma, Ferring, Otsuka Pharma, Pfizer, Schering-Plough, and UCB. Stefan Schreiber reports receiving consulting fees from Abbot Laboratories, Schering-Plough and its subsidiary Essex Pharma Solvay, and UCB; receiving lecture fees from Abbott Laboratories, Essex/Schering Plough, and UCB Pharma; and receiving grant support from Abbott and UCB Pharma. Ian C. Lawrance reports serving on the scientific advisory board and receiving consulting fees from Merck & Co, Abbott Laboratories, Pharmatel Fresenius Kabi, Janssen-Cilag Pharmaceuticals, Ferring Pharmaceuticals, and Schering-Plough; and receiving grant support from Abbott Laboratories and Orphan Australia. Stephen B. Hanauer reports serving as a consultant to and has been involved in clinical research with Abbot Laboratories, Bristol-Myers Squibb, Centocor, Elan Pharmaceuticals, Ferring Pharmaceuticals, Genentech, Proctor & Gamble, Prometheus, Salix, Shire, and UCB Pharma and serving as a consultant for AstraZeneca, GlaxoSmithKline, and Millennium Pharmaceuticals. Ralph Bloomfield is an employee of UCB. William J. Sandborn has received research support and served as a consultant for UCB Pharma, Centocor, and Abbott Laboratories.
Funding This study was funded by UCB, Brussels, Belgium.